SynthesisClinics (Sao Paulo, Brazil)2020
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer.
Synthesis in Clinics (Sao Paulo, Brazil), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Coagulation parameters in lung cancer patients: A systematic review and meta-analysis.Journal of clinical laboratory analysis · 2022Pooled it
- Predictive risk model for bone metastasis in intermediate-risk prostate cancer: a single-center retrospective analysis.Scientific reports · 2026Article
- Dynamic changes in D-dimer during first-line therapy and their association with overall survival in advanced lung cancer: a retrospective study.American journal of cancer research · 2026Article
- A Non-Endoscopic Dynamic Nomogram for Atrophic Gastritis Risk Stratification Based on Serum Indicators and Clinical Factors.Journal of inflammation research · 2026Article
- Plasma Fibrinogen Predicts Response to Immune Checkpoint Inhibitor by Inflammatory Tumor Microenvironment in Esophageal Cancer.Cancer medicine · 2026Article
- Development and validation of a machine-learning-based triage model incorporating systemic inflammatory, nutritional, coagulation, and tumor marker parameters for identifying baseline distant metastasis in lung cancer.Frontiers in oncology · 2026Article
- Article
- Plasma fibrinogen levels towards cancer incidence: a systematic review and meta-analysis of epidemiological studies.Discover oncology · 2025Article
- The diagnostic value of inflammatory markers in bone metastasis of prostate cancer at initial prostate biopsy.Frontiers in oncology · 2025Article
- Establishment and validation of a prediction model for gastric cancer with perineural invasion based on preoperative inflammatory markers.Translational cancer research · 2024Article
- Machine learning models to predict systemic inflammatory response syndrome after percutaneous nephrolithotomy.BMC urology · 2024Article
- Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival of patient in non-small cell lung cancer treated with surgery.Journal of thoracic disease · 2023Article
- The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer.European journal of medical research · 2023Article
- A new prognostic model for glioblastoma multiforme based on coagulation-related genes.Translational cancer research · 2023Article
- Impact of Fibrinogen, Fibrin Thrombi, and Thrombin on Cancer Cell Extravasation Using In Vitro Microvascular Networks.Advanced healthcare materials · 2023Article
- FAR Ratio as Prognostic Biomarker in AMI.SN comprehensive clinical medicine · 2023Article
- Development and validation of a nomogram based on neutrophil-to-lymphocyte ratio and fibrinogen-to-lymphocyte ratio for predicting recurrence of colorectal adenoma.Journal of gastrointestinal oncology · 2022Article
- Preoperative low absolute lymphocyte count to fibrinogen ratio correlated with poor survival in nonmetastatic colorectal cancer.World journal of surgical oncology · 2022Article
- The Prognostic value of the Fibrinogen to pre-albumin ratio in malignant tumors of the digestive system: a systematic review and meta-analysis.Cancer cell international · 2022Review
- The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma.Journal of personalized medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many researchers have shown that pretreatment plasma fibrinogen levels are closely correlated with the prognosis of patients with lung cancer (LC). In this study, we thus performed a meta-analysis to systematically assess the prognostic value of pretreatment plasma fibrinogen levels in LC patients. A computerized systematic search in PubMed, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI) was performed up to March 15, 2018. Studies with available data on the prognostic value of plasma fibrinogen in LC patients were eligible for inclusion. The pooled hazard ratios (HRs) and odd ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the correlation between pretreatment plasma fibrinogen levels and prognosis as well as clinicopathological characteristics. A total of 17 studies with 6,460 LC patients were included in this meta-analysis. A higher pretreatment plasma fibrinogen level was significantly associated with worse overall survival (OS) (HR: 1.57; 95% CI: 1.39-1.77; p=0.001), disease-free survival (DFS) (HR: 1.53; 95% CI: 1.33-1.76; p=0.003), and progression-free survival (PFS) (HR: 3.14; 95% CI: 2.15-4.59; p<0.001). Furthermore, our subgroup and sensitivity analyses demonstrated that the pooled HR for OS was robust and reliable. In addition, we also found that a higher fibrinogen level predicted advanced TNM stage (III-IV) (OR=2.18, 95% CI: 1.79-2.66; p<0.001) and a higher incidence of lymph node metastasis (OR=1.74, 95% CI: 1.44-2.10; p=0.02). Our study suggested that higher pretreatment plasma fibrinogen levels predict worse prognoses in LC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.